Sustained Organic Revenue GrowthMedicover has delivered multi-year, double-digit organic growth, with FY25 organic +12.7% and Q4 organic +10.6%. Durable top-line momentum across healthcare and diagnostics supports scale economics, network expansion and long-term demand visibility, underpinning margin recovery and capacity investments over the next 2–6 months.

Improving Cash Generation And FCFOperating cash flow and free cash flow have stepped up materially (FY25 operating cash €343.7m; FCF €185.6m). Strong cash conversion provides durable funding for maintenance and growth CapEx (~6–7% of revenue), supports deleveraging plans and shareholder returns, and reduces dependence on external financing over the medium term.

Clear 3‑year Targets And Integration ProgressManagement has articulated explicit 2028 financial targets and a leverage ceiling, while reporting near-complete SYNLAB and Sports & Wellness integration. This clear strategic roadmap and visible M&A execution increase management accountability, improve potential scale benefits, and support sustainable margin and ROIC improvement if execution continues as planned.

Bears Say

Elevated Leverage And Rising DebtLeverage has increased materially (debt from €367M in 2020 to €1,440M in 2025; D/E ~2.67), reducing financial flexibility. High gross debt limits the firm's ability to absorb shocks, constrains incremental M&A or expansion without deleveraging, and raises refinancing and interest-rate sensitivity risks over the next several quarters.

Regulatory Pricing Pressure In GermanyReimbursement reform in Germany has structurally reduced diagnostic pricing, muting price contribution even as volumes rose. Given Germany's scale in diagnostics, persistent regulatory pricing headwinds could compress segment margins and limit EBITDA leverage, creating a multi-quarter ceiling on profitability improvements absent offsetting actions.

Execution And Integration RisksOperational execution risks are evident: immature hospitals incurred losses (EUR 3.1m), some SYNLAB synergies remain unrealized, and an India strike disrupted government-pay services. These operational frictions can persist through multiple quarters, delaying EBITDA conversion, cash recovery and full benefit from recent acquisitions.

MCOV.B FAQ

What was Medicover AB’s price range in the past 12 months?

Medicover AB lowest stock price was kr183.40 and its highest was kr295.00 in the past 12 months.

What is Medicover AB’s market cap?

Medicover AB’s market cap is kr31.93B.

When is Medicover AB’s upcoming earnings report date?

Medicover AB’s upcoming earnings report date is Apr 29, 2026 which is in 65 days.

How were Medicover AB’s earnings last quarter?

Medicover AB released its earnings results on Feb 10, 2026. The company reported kr1.387 earnings per share for the quarter, beating the consensus estimate of kr1.323 by kr0.064.

Is Medicover AB overvalued?

According to Wall Street analysts Medicover AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicover AB pay dividends?

Medicover AB pays a Annually dividend of kr1.448 which represents an annual dividend yield of 0.66%. See more information on Medicover AB dividends here

What is Medicover AB’s EPS estimate?

Medicover AB’s EPS estimate is 1.55.

How many shares outstanding does Medicover AB have?

Medicover AB has 74,428,720 shares outstanding.

What happened to Medicover AB’s price movement after its last earnings report?

Medicover AB reported an EPS of kr1.387 in its last earnings report, beating expectations of kr1.323. Following the earnings report the stock price went up 8.148%.

Which hedge fund is a major shareholder of Medicover AB?

Currently, no hedge funds are holding shares in SE:MCOV.B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicover AB

Medicover AB (MCOV.B) is a leading healthcare and diagnostic services provider based in Sweden. The company operates across various sectors including healthcare services, diagnostics, and health insurance. Medicover offers a wide range of core products and services, such as outpatient and inpatient care, preventive healthcare services, and laboratory diagnostics, catering to both individual patients and corporate clients across Europe and Asia. The company aims to enhance the quality of healthcare through innovative solutions and comprehensive services.